文献速递免疫规划传染病防控与疫情报告

轮状病毒减毒活疫苗作为感染挑战模型的初步研究

A pilot study on use of live attenuated rotavirus vaccine (Rotarix™) as an infection challenge model.
PubMed 文献 · Vaccine · 2020-10-05

在22名赞比亚婴儿中开展开放标签探索性研究,于6周和10周龄接种两剂Rotarix™,第二剂视为减毒病毒挑战。以NSP2 qPCR检测粪便排毒,第二剂后平均排毒指数显著低于第一剂,提示首剂诱导黏膜免疫,支持将Rotarix™用作减毒感染挑战模型。

要点

  • 第二剂后粪便排毒指数显著低于第一剂(5.0 vs 10.4 copies/g,p<0.0001)。
  • 首剂后第3天排毒高、第5天达峰;第二剂后第3天低并逐渐下降。
  • 第28天血清阳转与挑战后排毒减少相关但无统计学显著性(p=0.774)。

核心结论

  • 第二剂Rotarix™后排毒较第一剂减少,与首剂诱导黏膜免疫一致,支持其作为减毒感染挑战模型。

研究设计与样本

  • 开放标签探索性研究,纳入22名赞比亚婴儿,于6周和10周龄接种两剂标准剂量Rotarix™,第二剂视为减毒病毒挑战。
  • 每剂后第0、3、5、7、14、28天采集唾液、粪便和血清,主要结局为NSP2 qPCR检测的粪便轮状病毒排毒。

主要发现

  • 第一剂后第3天排毒高、第5天达峰;第二剂后第3天排毒低并在多数婴儿中逐渐下降至第14天。
  • 第二剂后平均排毒指数在所有婴儿和时间点显著低于第一剂(5.0 copies/g [95%CI: 0.3-9.7] vs 10.4 copies/g [95%CI: 6.2-14.6];p<0.0001;rho=0.20,SD=4.97)。
  • 第28天血清阳转与挑战后排毒平均减少-1.03(95%CI: -8.07, 6.01)相关,但无统计学显著性(p=0.774)。
  • 唾液与血清第28天较第0天IgA滴度倍数变化呈边缘正相关(Spearman r=0.69;p=0.086)。

临床怎么用

  • 提示Rotarix™可用作婴儿减毒活病毒挑战模型,用于快速评估新候选疫苗。
  • 排毒指数与血清阳转的关系需更大样本验证,暂不能作为免疫替代终点。

局限性

  • 探索性小样本(22名婴儿)研究,结果需在更大队列中验证。
  • 血清阳转与排毒减少的关联未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rotavirus remains the commonest cause of dehydrating diarrhoea, particularly in developing countries. Human infection challenge studies in children in these countries offers an opportunity to rapidly evaluate new vaccine candidates that may have improved efficacy. We evaluated use of Rotarix™ as a live-attenuated challenge agent. METHODS: We undertook an open label, exploratory study in infants receiving two standard doses of Rotarix™ at 6 and 10 weeks of age in a cohort of 22 Zambian infants. The first vaccine dose was considered as primary vaccination, and the second at day 28 as a live-attenuated virus challenge. Saliva, stool and serum samples were collected on days 0, 3, 5, 7, 14, and 28 following each dose. The primary outcome was stool shedding of rotavirus, determined by NSP2 qPCR. We calculated mean shedding index as average of natural logarithm of viral copies per gram of stool. FINDINGS: After the first dose, viral shedding was high at day 3, peaked by day 5. After the second dose, viral shedding at day 3 was low and reduced gradually in most infants until day 14. Mean shedding index was significantly lower post dose 2 across all infants and timepoints (5.0 virus copies/g of stool [95%CI: 0.3-9.7] vs 10.4 virus copies/g of stool [95%CI: 6.2-14.6]; p-value < 0.0001; rho = 0.20, SD = 4.97. Seroconversion at day 28 was associated with a mean reduction of -1.03 (95%CI = -8.07, 6.01) in viral shedding after challenge dose but this was not statistically significant (p = 0.774). A borderline positive correlation between fold-change in IgA titre at day 28 from day 0 in saliva and serum was observed; Spearman's correlation coefficient, r = 0.69; p = 0.086. INTERPRETATION: Shedding after the 'challenge' dose was reduced compared with the first dose, consistent with the induction of mucosal immunity by the first dose. This supports the use of Rotarix vaccine as a live-attenuated infection challenge. FUNDING: Medical Research Council (UK) through the HIC-Vac Network.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chilengi R, Simuyandi M, Chibuye M, et al. A pilot study on use of live attenuated rotavirus vaccine (Rotarix™) as an infection challenge model. Vaccine. 2020. PMID: 33032844. doi:10.1016/j.vaccine.2020.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。